Express Pharma
Home  »  Latest Updates  »  Claris receives ANDA approval for Bupivacaine injection

Claris receives ANDA approval for Bupivacaine injection

12

It is a local or regional anesthesia used as a long-acting anesthetic during surgical procedures

Claris Lifesciences has received the Abbreviated New Drug Application (ANDA) approval for Bupivacaine hydrochloride in 8.25 per cent Dextrose Injection USP, 7.5 mg/mL, Single-dose Ampules with 2ml fill volumes, in the US.

With this approval Claris now has a total of 15 approvals and 25 under approval ANDAs, the total addressable market size of the approved ANDAs is estimated to be a little above $ 300 million. Claris expects more product approvals during the year, which will allow it to continue its growth in the US market.

Bupivacaine hydroxhloride in dextorse injection is a local or regional anesthesia used as a long-acting anesthetic during surgical procedures.

Comments are closed.